Compare the evidence

Sources, findings and their limits
Source and designPopulation or scopeFindingLimits
Official Atopica label [1]Dog-scoped combination; general concentration warning also mentions catsKetoconazole-associated increase in ciclosporin concentrations is clinically relevant.Dog concentration examples are not a universal multiplier or a feline adjustment plan.
D’mello et al., 1989 — pharmacokinetic experiment [2]Five male Beagles; IV ciclosporin ± oral ketoconazole; surgically modified bile-collection modelSystemic clearance fell from 7.0 to 2.5 ml/min/kg; no significant change in distribution volume or unbound fraction.Abstract reviewed; small experimental model, not a current oral-product field trial or cat study.
Archer et al., 2014 — narrative review [3]Oral ciclosporin in dogsDescribes formulation variability, individual responses and interpretation of whole-blood monitoring.Exposure measurements do not by themselves establish remission, absence of toxicity or a universal dose adjustment.

Can ketoconazole increase ciclosporin blood concentrations in dogs?

Yes. Atopica calls the concentration increase with azoles such as ketoconazole clinically relevant in dogs and cats. The concern is increased ciclosporin exposure; this article examines the dog-scoped combination and supporting canine pharmacokinetic evidence. [1]

What mechanism does the official source describe?

Atopica discusses inhibition or induction of enzymes involved in ciclosporin metabolism, particularly CYP3A4, and names ketoconazole as increasing concentrations. This explains the direction of concern without predicting an individual dog's exposure. [1]

Does the dog concentration example apply to every patient?

No. The label's dog-specific concentration example applies to stated conditions, not every product, regimen or patient. It cannot be converted into a universal dose multiplier or administration interval. [1]

Can this interaction be used as a routine cost-saving dosing strategy?

Not automatically. Atopica places possible adjustments in clinically justified, veterinarian-directed circumstances. Increased exposure alone is not a recommendation to add ketoconazole or reduce ciclosporin for cost savings. [1]

Does a reference to cats make dog instructions transferable to cats?

No. The general concentration warning covers dogs and cats, but the more specific concentration and interval discussion identifies dogs. Dog adjustment examples do not establish an appropriate feline regimen. [1]

What should be checked before the combination is prescribed or changed?

Review the exact ciclosporin formulation, ketoconazole product and route, other medicines and clinical response. If concentration monitoring is chosen, administration and sampling details also matter. The prescribing veterinarian must assess any proposed change. [1]

Evidence appraisal

Direct experimental canine data support a pharmacokinetic mechanism. In a 1989 study, D’mello and colleagues gave intravenous ciclosporin to five male Beagles in a surgically modified bile-collection model, with and without oral ketoconazole. Reported systemic clearance fell from 7.0 to 2.5 ml/min/kg; the investigators found no significant change in steady-state volume of distribution or plasma unbound fraction. They interpreted inhibition of hepatic drug-metabolising enzymes as the main explanation for increased ciclosporin concentration. [2]

This is a small mechanistic study, not a field trial of current oral veterinary products. Intravenous ciclosporin and the experimental model limit direct transfer to oral absorption, diseased patients or cats. The 2014 canine review also describes variable formulation bioavailability and individual responses during ketoconazole use. The measured clearance change is therefore evidence for the direction of interaction, not a universal dose-reduction formula. [2] [3]

Clinical interpretation and follow-up

The label's concentration warning agrees with the direction of the small canine experiment. If monitoring is selected, the canine review supports whole-blood sampling and attention to assay and timing. Interpretation still requires formulation, administration history, indication and clinical response. [1] [3] [2]

Concentration is an exposure endpoint, not remission or absence of toxicity. Published monitored co-administration does not establish a universal target across immune-mediated diseases or justify unsupervised ketoconazole addition. The experimental clearance change cannot select an individual adjustment. [2] [3]

Questions for veterinary review

Editorial discussion checklist for your veterinarian:

  • Verify the actual ciclosporin and ketoconazole products and the intended clinical purpose of each.
  • Distinguish the shared dog-and-cat warning from dog-specific examples in the label.
  • Have the veterinarian decide whether exposure assessment or a change in the treatment plan is warranted.

Catalogue review status and evidence limits

The catalogue records contain verified direct evidence (dog): a species-scoped official-label statement, not necessarily a controlled interaction trial. The linked label PDF was also checked for publication.

A verified warning does not establish an individual animal's outcome, a patient-specific dose or independent clinical review. No matching rule does not prove safety.

Evidence sources

Citation scope: official labels support the interaction warnings; research and guidelines provide separately identified context. Each citation shows its document version or literature type and review scope. Catalogue identifiers may refer to earlier versions; this article uses the linked label PDF. Repeated labels are not independent studies. Source URLs and product authorizations may change.

  1. VMD: Atopica 100 mg/ml Oral Solution for Cats and Dogs — Summary of Product Characteristics

    Evidence type: Official product label. Revised September 2025. 4.8, interactions. Page 5. Source checked: . Open official VMD source

  2. Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs.

    D'mello A et al. Res Commun Chem Pathol Pharmacol. 1989;64(3):441-454. Evidence type: Primary study. Review scope: Abstract and bibliographic record. Source checked: . Open research source

  3. Oral cyclosporine treatment in dogs: a review of the literature.

    Archer TM et al. J Vet Intern Med. 2014;28(1):1-20. Evidence type: Narrative review. Review scope: Full text. Source checked: . Open research source

Content responsibility: ZooDDI. For veterinary discussion, not diagnosis, prescribing or emergency care. No independent veterinary clinical review has been completed.

Check a complete medication regimen